Nano Dimension has entered into a non-binding term sheet for a proposed business combination with Infinite Epigenetics, Inc., an AI-powered preventive health and diagnostics company. The transaction would pivot Nano Dimension into the high-growth healthcare AI sector, with the combined company operating as Infinite Epigenetics and trading on Nasdaq under the proposed ticker "IEAI."
Key Details
- Transaction Terms: On June 15, 2026, Nano Dimension (NNDM) signed a non-binding term sheet to acquire 100% of Infinite Epigenetics in a stock-for-stock transaction. The deal is subject to a 30-day exclusivity period, due diligence, and execution of a definitive agreement.
- Valuation & Ownership: The agreement values Infinite Epigenetics at $890 million (less a premium). NNDM's valuation will be based on its net cash at closing plus a 20% premium. Current NNDM shareholders are expected to retain a meaningful minority stake in the combined entity.
- Post-Merger Structure: The combined company will be led by Infinite Epigenetics' CEO, Dr. Matthew Dawson. Existing NNDM shareholders will also receive a Contingent Value Right (CVR) for net proceeds from the disposition of certain NNDM legacy assets.
- Strategic Rationale: The merger is the result of a multi-month strategic review by NNDM's board to deploy its capital base and Nasdaq listing into a more compelling long-term value creation opportunity after evaluating approximately 20 companies.